FDA Evaluates Alli For Potential Serious Risk Of Kidney Stones
By
Elizabeth Crawford / Email the Author / “The Tan Sheet” Jan. 16, 2012, Vol. 20, No. 03
OTCs / Word Count: 1100 / Article # 05120116007
Executive Summary
FDA adds kidney stones to the list of potential signals of a serious risk for alli based on AER information gathered between July and October 2011. GSK, which is confident in the safety and efficacy of alli when used correctly, placed the only OTC weight-loss drug on the auction block last April, but needs a buyer.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.